Kallikrein 13 antibody (AA 262-277)

Catalog No. ABIN289487

Product Details anti-Kallikrein 13 Antibody

Target: Kallikrein 13 (KLK13) (Kallikrein-Related Peptidase 13 (KLK13))

Binding Specificity: AA 262-277

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This Kallikrein 13 antibody is un-conjugated

Application: Western Blotting (WB)

Purification: Affinity chromatography purified

Immunogen: KLK-L4 antibody was raised in rabbit using AA 262-277 [IRKYETQQQKWLKGPQ] of the human KLK-L4 protein as the immunogen.

Isotype: IgG

Application Details

Application Notes: WB: 1:500-1:1,000
Optimal conditions should be determined by the investigator.

Restrictions: For Research Use only

Handling

Concentration: Lot specific

Buffer: Affinity purified IgG supplied in PBS with 0.02 % NaN3.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium Azide: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Handling Advice: Avoid repeated freeze/thaw cycles.
Dilute only prior to immediate use.

Storage: 4 °C/-20 °C

Storage Comment: Store at 4 °C for short term storage. Aliquot and store at -20 °C for long term storage.

Target Details for Kallikrein 13

Target: Kallikrein 13 (KLK13) (Kallikrein-Related Peptidase 13 (KLK13))

Alternative Name: KLK-L4 (KLK13 Products)

Synonyms: KLK-L4 antibody, KLKL4 antibody, Egfbp-2 antibody, mGk-13 antibody, kallikrein related peptidase 13 antibody, kallikrein related-peptidase 13 antibody, KLK13 antibody, Klk13 antibody

Background: Kallikreins are a subgroup of serine proteases and are implicated in carcinogenesis. The novel KLK gene, KLK-L4, is expressed in a variety of tissues including prostate, salivary gland, breast, and testis. Its expression is regulated by steroid hormones in breast cancer cell lines may be involved in the pathogenesis and/or progression of breast cancer.

Pathways: Complement System